CAR T-cell therapy tops this week's research roundup, with news about the experimental immunotherapy designed to re-engineer a patient's cells to fight cancer making late-breaking and captivating headlines across the nation.
Synapses were firing throughout the conference room in the Colket Translational Research Building as attendees at the 2017 Research Institute Scientific Symposium held May 2 learned about their colleagues' intriguing research endeavors. The four sessions' themes aligned smartly with the Research Institute's strategic planning process and overall mission of the Children's Hospital of Philadelphia.
Despite advances in T-cell acute lymphoblastic leukemia treatment, between 15 and 20 percent of children who achieve an initial complete remission will relapse. They may need more intensive therapy or alternative approaches, but physicians do not yet have a reliable way of predicting which patients are at high-risk of relapse.